Beta Bionics, Inc. Common Stock BBNX

Beta Bionics, Inc. es una empresa de dispositivos médicos en etapa comercial dedicada al diseño, desarrollo y comercialización de diversas soluciones para mejorar la salud de las personas con diabetes que requieren insulina (PWD, por sus siglas en inglés). El producto de la empresa, el Páncreas Biónico iLet (iLet), es un dispositivo de administración de insulina aprobado por la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) que utiliza algoritmos adaptativos de circuito cerrado para determinar de forma autónoma cada dosis de insulina sin necesidad de que el usuario cuente la ingesta de carbohidratos. iLet se utiliza para el tratamiento de la diabetes tipo 1 (T1D). Las soluciones de la empresa incluyen iLet para adultos, iLet para niños, la aplicación Bionic Circle y el Simulador iLet. La empresa se encuentra en las primeras etapas del desarrollo de una bomba de insulina diseñada para adherirse directamente a la piel y administrar insulina sin necesidad de tubos, comúnmente conocida en la industria de la diabetes como una bomba de parche. También se encuentra en las primeras etapas del desarrollo de una configuración bihormonal del iLet.

• GlobeNewswire Inc. 3 oct

  ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

  A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns including device malfunctions and dangerously high insulin dosing causing hypoglycemic events. The lawsuit claims Beta Bionics failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

  

• GlobeNewswire Inc. 2 oct

  Kaplan Fox Notifies Beta Bionics, Inc. (NASDAQ: BBNX) Investors of an Upcoming Lead Plaintiff Deadline on November 3, 2026

  A class action lawsuit has been filed against Beta Bionics (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious device malfunctions in its iLet insulin pump caused by an overly aggressive dosing algorithm. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about complaint severity, leading to a 37% stock decline. The lead plaintiff deadline is November 3, 2026.

  

• GlobeNewswire Inc. 2 oct

  Kaplan Fox Alerts GoDaddy Inc. (NYSE: GDDY) Investors to an Approaching Lead Plaintiff Deadline on October 20, 2026

  A class action lawsuit has been filed against GoDaddy Inc. for allegedly making false and misleading statements about customer growth strategy while implementing promotional discounts that materially harmed bookings growth. The company's stock declined over 14% on February 25, 2026, following disclosure of sharply decelerated bookings growth of only 5% in Q4 2025. The lead plaintiff deadline is October 20, 2026.

  

• GlobeNewswire Inc. 1 oct

  רוזן, משרד מוביל בפריסה ארצית המייצג משקיעים, מעודד את משקיעי חברת Beta Bionics, Inc לשכור ייעוץ משפטי לקראת מועד אחרון חשוב במסגרת תביעה ייצוגית בניירות ערך – BBNX

  The Rosen Law Firm is reminding investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 of the November 3, 2026 deadline to file a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump system, which the FDA found to have serious malfunctions causing dangerous insulin levels and hypoglycemic events. The company allegedly failed to implement corrective measures despite FDA concerns.

  

• GlobeNewswire Inc. 30 sept

  Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

  Beta Bionics faces a securities class action lawsuit alleging the company failed to disclose that its iLet insulin pump had a malfunctioning automated dosing algorithm causing dangerously high insulin delivery and hypoglycemic events. The company allegedly received thousands of complaints it failed to report to the FDA, and an FDA Form 483 identified over 18,000 unreported complaints. Investors with losses exceeding $100,000 have until November 3, 2026 to file lead plaintiff applications.